We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+13.44%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$329M
AUM Growth
+$94M
Cap. Flow
+$80.7M
Cap. Flow %
24.51%
Top 10 Hldgs %
27.28%
Holding
112
New
38
Increased
35
Reduced
8
Closed
25

Top Buys

Rank Stock Value
1
NVS icon
Novartis
NVS
+$7.49M
2
KTWO
K2M Group Holdings, Inc
KTWO
+$6.3M
3
SYK icon
Stryker
SYK
+$5.17M
4
MEDP icon
Medpace
MEDP
+$4.63M
5
ABT icon
Abbott
ABT
+$4.5M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$6.94M
2
BMY icon
Bristol-Myers Squibb
BMY
+$6.34M
3
UHS icon
Universal Health Services
UHS
+$5.36M
4
MCK icon
McKesson
MCK
+$5.13M
5
ACH
Accendra Health
ACH
+$4.16M

Sector Composition

Rank Sector Weight
1 Healthcare 62.31%
2 Financials 2.43%
3 Industrials 2.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NDRM
76
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$743K 0.23%
40,183
+15,500
+63% +$269K
AVGR
77
CALL
DELISTED
Avinger, Inc. Common Stock
AVGR
$716K 0.22%
+1
New +$661K
OCRX
78
DELISTED
Ocera Therapeutics, Inc.
OCRX
$657K 0.2%
248,962
+117,962
+90% +$295K
ARAY icon
79
CALL
Accuray
ARAY
$34.6M
$637K 0.19%
+100,000
New +$545K
ADYX
80
DELISTED
Adynxx Inc
ADYX
$466K 0.14%
9,717
– –
TTOO
81
DELISTED
T2 Biosystems, Inc
TTOO
$441K 0.13%
+12
New +$394K
NVCN
82
DELISTED
Neovasc Inc.
NVCN
$310K 0.09%
24
+14
+140% +$196K
STDY
83
DELISTED
SteadyMed Ltd
STDY
$285K 0.09%
79,434
+50,676
+176% +$173K
ARRY
84
DELISTED
Array Biopharma Inc
ARRY
$203K 0.06%
+30,000
New +$116K
AGRX
85
DELISTED
Agile Therapeutics
AGRX
$174K 0.05%
+12
New +$171K
OCGN icon
86
Ocugen
OCGN
$465M
$142K 0.04%
+737
New +$115K
ADMA icon
87
ADMA Biologics
ADMA
$2.22B
– –
-36,500
Closed -$217K
ATRC icon
88
AtriCure
ATRC
$2.18B
– –
-110,098
Closed -$1.56M
BDX icon
89
PUT
Becton Dickinson
BDX
$49.4B
– –
-38,438
Closed -$6.36M
BMY icon
90
Bristol-Myers Squibb
BMY
$130B
– –
-86,250
Closed -$6.34M
CVS icon
91
CVS Health
CVS
$120B
– –
-40,000
Closed -$3.83M
MCK icon
92
McKesson
MCK
$105B
– –
-27,500
Closed -$5.13M
MDT icon
93
Medtronic
MDT
$116B
– –
-80,000
Closed -$6.94M
ACH
94
Accendra Health
ACH
$96.9M
– –
-111,400
Closed -$4.16M
PFE icon
95
Pfizer
PFE
$152B
– –
-124,029
Closed -$4.14M
TMO icon
96
PUT
Thermo Fisher Scientific
TMO
$224B
– –
-25,000
Closed -$3.69M
TNXP icon
97
Tonix Pharmaceuticals
TNXP
$212M
– –
0
– -$567K
UHS icon
98
Universal Health Services
UHS
$9.94B
– –
-40,000
Closed -$5.36M
XLV icon
99
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$43.9B
– –
-90,000
Closed -$6.45M
NUVA
100
DELISTED
NuVasive, Inc.
NUVA
– –
-25,000
Closed -$1.49M
1 2 3
4
5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q3 2016 Portfolio in Review

As of Q3 2016, Pura Vida Investments held 112 positions worth $329M, up 40% from $235M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Pura Vida Investments deployed $80.7M of net new capital in Q3 2016, opening 38 new positions and adding to 35 existing holdings. Its largest new stake was Novartis: 102,812 shares worth $7.27M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 63% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Insulet, an estimated $2.8M trimmed.

  • Pura Vida Investments's largest Q3 2016 buy was Novartis: 102,812 shares worth $7.27M.
  • Pura Vida Investments added most to Stryker in Q3 2016, an estimated $5.17M increase.
  • Pura Vida Investments's biggest Q3 2016 reduction was Insulet, cutting an estimated $2.8M.
  • Pura Vida Investments fully exited Medtronic in Q3 2016, selling an estimated $6.94M.
  • Pura Vida Investments's ten largest holdings make up 27% of its $329M portfolio in Q3 2016.
  • Pura Vida Investments opened 38 new positions and closed 25 in Q3 2016.
  • Pura Vida Investments's portfolio value rose 40% quarter-over-quarter to $329M.

Based on Pura Vida Investments's 13F filing for Q3 2016, filed 14 Nov 2016.